Pennant Investors, LP Igm Biosciences, Inc. Transaction History
Pennant Investors, LP
- $402 Million
- Q1 2024
A detailed history of Pennant Investors, LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 64,900 shares of IGMS stock, worth $540,617. This represents 0.16% of its overall portfolio holdings.
Number of Shares
64,900
Previous 64,900
-0.0%
Holding current value
$540,617
Previous $539,000
16.14%
% of portfolio
0.16%
Previous 0.12%
Shares
1 transactions
Others Institutions Holding IGMS
# of Institutions
90Shares Held
20.5MCall Options Held
11.1KPut Options Held
5.1K-
Baker Bros. Advisors LP New York, NY4.09MShares$34.1 Million0.5% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.89MShares$32.4 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.08MShares$25.7 Million1.6% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$25.6 Million1.17% of portfolio
-
Goldman Sachs Group Inc New York, NY1.28MShares$10.7 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $241M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...